Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Neal Clark"'
Autor:
Marit Muri Holmen, Christoffer Jonsrud, Anita Vabø, Anne Irene Hagen, Ping Sun, Neal Clark, Pål Møller, Lovise Maehle, Astrid Stormorken, Steven A. Narod
Publikováno v:
Breast Cancer Research and Treatment. 139:155-161
We report the 5- and 10-year survival rate of women diagnosed with breast cancer in the context of an annual MRI-based surveillance program. In 2001, as part of a national initiative, women in Norway with a BRCA1 mutation were offered annual screenin
Publikováno v:
Human Mutation. 32:568-571
A method for SImplified rapid Segregation Analysis (SISA) to assess penetrance and expression of genetic variants in pedigrees of any complexity is presented. For this purpose the probability for recombination between the variant and the gene is zero
Autor:
Astrid Stormorken, Sara González, Neal Clark, Ignacio Blanco, Pål Møller, Lovise Maehle, Eli Marie Grindedal, John Burn, Hans F. A. Vasen, Gabriel Capellá
Publikováno v:
Familial Cancer. 8:145-151
Endometrial cancer is frequent in MMR-mutation carriers. Estimates of annual incidence rates have, however, been based on retrospective studies. The purpose of our study was to prospectively assess the incidence rates of endometrial cancer in women e
Autor:
Eivind Hovig, Kjell Løvslett, Pål Møller, Lovise Mæhle, Jaran Apold, Anne Irene Hagen, Neal Clark, Anita Vabø, Bent Fiane
Publikováno v:
European Journal of Cancer. 43:1713-1717
Ten BRCA mutations were demonstrated to be frequent in the Norwegian population. We present maps verifying the uneven distribution of prevalences according to municipality. We tested incident breast cancer cases treated in Mid-Norway from 1999 onward
Publikováno v:
Scandinavian Journal of Gastroenterology. 42:611-617
In recent years persons at risk for colorectal cancers (CRC) have been subjected to follow-up with colonoscopy in many centres. There is, however, limited knowledge about the effect of such interventions. The objective of this study was to report the
Publikováno v:
Clinical genetics. 83(1)
Moller P, Maehle L, Vabo A, Clark N, Sun P, Narod SA. Age-specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway. Incidence rates of breast cancer among women with a BRCA1 mutation vary according to their reproductive h
Autor:
Neal Clark, Pål Møller
Publikováno v:
Human mutation. 32(5)
CGEN (Clinical GENetics) is a software application built to manage the IT requirements of genetic clinics with the specific focus to collect well-organized and verified data for genetic research. This article describes the functionality of CGEN, the
Autor:
Lovise Maehle, Eli Marie Grindedal, Rune Kvåle, Astrid Stormorken, Ros Eeles, Inger Marie Bowitz-Lothe, Susan Shanley, Neal Clark, Stefan Magnus Landrø, Pål Møller
Publikováno v:
Cancer epidemiology, biomarkersprevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 18(9)
Genetic predisposition to prostate cancer includes multiple common variants with a low penetrance (single nucleotide polymorphisms) and rare variants with higher penetrance. The mismatch repair (MMR) genes MLH1, MSH2, MSH6, and PMS2 are associated wi
Autor:
Bent Fiane, Marijke Van Ghelue, Jaran Apold, Kjell Løvslett, Neal Clark, Pål Møller, Lovise Maehle, Torbjørn Paulsen, Bjørn Hagen
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 14(22)
Purpose: Inherited ovarian cancer carries a serious prognosis. Prophylactic oophorectomy has been advocated. The degree to which inherited ovarian cancer is restricted to BRCA mutation carriers is not fully known. We wanted to determine the prevalenc
Autor:
Pål Møller, Anthony Howell, Jaran Apold, Helen Gregory, D. Gareth Evans, Fiona Lalloo, Anneke Lucassen, Marta M. Reis, C. Michael Steel, Neal Clark, Lovise Mæhle, E Anderson
Publikováno v:
International journal of cancer. 121(5)
Women with a family history of breast cancer are commonly offered regular clinical or mammographic surveillance from age 30. Data on the efficacy of such programmes are limited. Clinical, pathological and outcome data were recorded on all breast and